Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ballesteros, Lei Shi, J. Javitch (2001)
Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.Molecular pharmacology, 60 1
Desmopressin Binding in
K. Murzyn, T. Róg, G. Jezierski, Y. Takaoka, M. Pasenkiewicz-Gierula (2001)
Effects of phospholipid unsaturation on the membrane/water interface: a molecular simulation study.Biophysical journal, 81 1
T. Mirzadegan, G. Benkö, S. Filipek, K. Palczewski (2003)
Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin.Biochemistry, 42 10
(1998)
Reviewing Editor:
C. Barberis, B. Mouillac, T. Durroux (1998)
Structural bases of vasopressin/oxytocin receptor function.The Journal of endocrinology, 156 2
S. Acharya, S. Karnik (1996)
Modulation of GDP Release from Transducin by the Conserved Glu134-Arg135 Sequence in Rhodopsin*The Journal of Biological Chemistry, 271
P. Mannucci (2004)
Treatment of von Willebrand's Disease.The New England journal of medicine, 351 7
B. Koenig, G. Kontaxis, D. Mitchell, J. Louis, B. Litman, A. Bax (2002)
Structure and orientation of a G protein fragment in the receptor bound state from residual dipolar couplings.Journal of molecular biology, 322 2
(2000)
Pathophysiology of Water Metabolism: The Kidney,6th ed.; Philadelphia: W.B
B. White, P. Lawler, A. Riddell, I. Nitu‐Whalley, C. Hermans, C. Lee, S. Brown (2004)
Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand diseaseBritish Journal of Haematology, 126
A. Oksche, R. Schülein, C. Rutz, U. Liebenhoff, J. Dickson, H. Müller, M. Birnbaumer, W. Rosenthal (1996)
Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.Molecular pharmacology, 50 4
L. Barak, L. Ménard, S. Ferguson, A. Colapietro, M. Caron (1995)
The conserved seven-transmembrane sequence NP(X)2,3Y of the G-protein-coupled receptor superfamily regulates multiple properties of the beta 2-adrenergic receptor.Biochemistry, 34 47
P. Garcia, R. Onrust, S. Bell, T. Sakmar, H. Bourne (1995)
Transducin‐alpha C‐terminal mutations prevent activation by rhodopsin: a new assay using recombinant proteins expressed in cultured cells.The EMBO Journal, 14
M. Thibonnier, C. Auzan, Z. Madhun, P. Wilkins, L. Berti-Mattera, E. Clauser (1994)
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.The Journal of biological chemistry, 269 5
J. Ballesteros, S. Kitanovic, F. Guarnieri, P. Davies, Bernard Fromme, K. Konvička, L. Chi, R. Millar, J. Davidson, H. Weinstein, S. Sealfon (1998)
Functional Microdomains in G-protein-coupled ReceptorsThe Journal of Biological Chemistry, 273
Michael Schmidt, K. Baldridge, J. Boatz, S. Elbert, M. Gordon, J. Jensen, S. Koseki, N. Matsunaga, K. Nguyen, Shujun. Su, T. Windus, M. Dupuis, J. Montgomery (1993)
General atomic and molecular electronic structure systemJournal of Computational Chemistry, 14
W. Sawyer, M. Acosta, L. Balaspiri, J. Judd, M. Manning (1974)
Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity.Endocrinology, 94 4
M. Ślusarz, R. Ślusarz, R. Meadows, J. Trojnar, J. Ciarkowski (2004)
Molecular Dynamics of Complexes of Atosiban with Neurohypophyseal Receptors in the Fully Hydrated Phospholipid BilayerQsar & Combinatorial Science, 23
T. Okada, Y. Fujiyoshi, M. Silow, Javier Navarro, E. Landau, Y. Shichida (2002)
Functional role of internal water molecules in rhodopsin revealed by x-ray crystallographyProceedings of the National Academy of Sciences of the United States of America, 99
Reto Koradi, M. Billeter, K. Wüthrich (1996)
MOLMOL: a program for display and analysis of macromolecular structures.Journal of molecular graphics, 14 1
T. Sakmar (2002)
Structure of rhodopsin and the superfamily of seven-helical receptors: the same and not the same.Current opinion in cell biology, 14 2
W. Chan, N. Wo, L. Cheng, M. Manning (1996)
Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.The Journal of pharmacology and experimental therapeutics, 277 2
O. Becker, S. Shacham, Y. Marantz, S. Noiman (2003)
Modeling the 3D structure of GPCRs: advances and application to drug discovery.Current opinion in drug discovery & development, 6 3
L. Hunyady, M. Bor, A. Baukal, T. Balla, K. Catt (1995)
A Conserved NPLFY Sequence Contributes to Agonist Binding and Signal Transduction but Is Not an Internalization Signal for the Type 1 Angiotensin II Receptor (*)The Journal of Biological Chemistry, 270
N. Knoers, A. Ouweland, M. Verdijk, L. Monnens, B. Oost (1994)
Inheritance of mutations in the V2 receptor gene in thirteen families with nephrogenic diabetes insipidus.Kidney international, 46 1
M. Manning, L. Balaspiri, J. Moehring, J. Haldar, W. Sawyer (1976)
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.Journal of medicinal chemistry, 19 6
Eneko Urizar, S. Claeysen, X. Deupí, C. Govaerts, S. Costagliola, G. Vassart, L. Pardo (2005)
An Activation Switch in the Rhodopsin Family of G Protein-coupled ReceptorsJournal of Biological Chemistry, 280
U. Essmann, L. Perera, M. Berkowitz, T. Darden, Hsing-Chou Lee, L. Pedersen (1995)
A smooth particle mesh Ewald methodJournal of Chemical Physics, 103
S. Osawa, E. Weiss (1995)
The Effect of Carboxyl-terminal Mutagenesis of G on Rhodopsin and Guanine Nucleotide Binding (*)The Journal of Biological Chemistry, 270
D. Goodsell, G. Morris, A. Olson (1996)
Automated docking of flexible ligands: Applications of autodockJournal of Molecular Recognition, 9
Walter Rosenthal, A. Antaramián, Stephanie Gilbert, Mariel Birnbaumer (1993)
Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase.The Journal of biological chemistry, 268 18
W. Jorgensen, J. Tirado-Rives (1988)
The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin.Journal of the American Chemical Society, 110 6
Chouaib Tahtaoui, M. Balestre, P. Klotz, D. Rognan, C. Barberis, B. Mouillac, M. Hibert (2003)
Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors*Journal of Biological Chemistry, 278
T. Okada, M. Sugihara, A. Bondar, M. Elstner, P. Entel, V. Buss (2004)
The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.Journal of molecular biology, 342 2
J. Ballesteros, H. Weinstein (1995)
[19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptorsMethods in Neurosciences, 25
Alexander Scheer, Francesca Fanelli, Tommaso Costa, P. Benedetti, Susanna Cotecchia (1996)
Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation.The EMBO Journal, 15
H. Zingg (1996)
Vasopressin and oxytocin receptors.Bailliere's clinical endocrinology and metabolism, 10 1
S. Lethagen, K. Egervall, E. Berntorp, B. Bengtsson (1995)
The administration of desmopressin by nasal spray: a dose‐determination study in patients with mild haemophilia A or von Willebrand's diseaseHaemophilia, 1
G. Gimpl, F. Fahrenholz (2001)
The oxytocin receptor system: structure, function, and regulation.Physiological reviews, 81 2
M. Birnbaumer (1999)
Vasopressin receptor mutations and nephrogenic diabetes insipidus.Archives of medical research, 30 6
A. Colson, J. Perlman, A. Jinsi-Parimoo, D. Nussenzveig, R. Osman, M. Gershengorn (1998)
A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation.Molecular pharmacology, 54 6
Jong-Myoung Kim, C. Altenbach, M. Kono, D. Oprian, W. Hubbell, H. Khorana (2004)
Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge.Proceedings of the National Academy of Sciences of the United States of America, 101 34
R. Stenkamp, D. Teller, K. Palczewski (2002)
Crystal Structure of Rhodopsin: A G‐Protein‐Coupled ReceptorChemBioChem, 3
W. Hubbell, C. Altenbach, C. Hubbell, H. Khorana (2003)
Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking.Advances in protein chemistry, 63
A. Alewijnse, Henk Timmerman, Edwin Jacobs, Martine Smit, Edwin Roovers, Susanna Cotecchia, Rob Leurs (2000)
The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor.Molecular pharmacology, 57 5
C. Breton, Hichem Chellil, Majida Kabbaj-Benmansour, E. Carnazzi, R. Seyer, Sylvie Phalipou, D. Morin, T. Durroux, H. Zingg, C. Barberis, B. Mouillac (2001)
Direct Identification of Human Oxytocin Receptor-binding Domains Using a Photoactivatable Cyclic Peptide AntagonistThe Journal of Biological Chemistry, 276
Mikihiro Shibata, H. Kandori (2005)
FTIR studies of internal water molecules in the Schiff base region of bacteriorhodopsin.Biochemistry, 44 20
M. Manning, A. Olma, W. Kliś, A. Kolodziejczyk, E. Nawrocka, A. Misicka, J. Seto, Wilbur Sawyer (1984)
Carboxy terminus of vasopressin required for activity but not bindingNature, 308
Jeff Sands, D. Bichet
Physiology in Medicine: a Series of Articles Linking Medicine with Science Physiology in Medicine: Nephrogenic Diabetes Insipidus Web-only Cme Quiz Conversion of Figures into Slides
S. Hawtin, V. Wesley, J. Simms, Cymone Argent, Khalid Latif, M. Wheatley (2005)
The N-terminal juxtamembrane segment of the V1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling.Molecular endocrinology, 19 11
R. Ślusarz, M. Ślusarz, R. Kazmierkiewicz, B. Lammek (2003)
Molecular Modeling of Interaction of the Vasopressin Analogs with Vasopressin and Oxytocin ReceptorsQsar & Combinatorial Science, 22
M. Ślusarz, A. Giełdoń, R. Ślusarz, J. Ciarkowski (2006)
Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors—molecular dynamics study of the activated receptor–vasopressin–Gα systemsJournal of Peptide Science, 12
E. Kojro, R. Postina, S. Gilbert, Frank Bender, Gerd Krause, Falk Fahrenholz (1999)
Structural requirements for V2 vasopressin receptor proteolytic cleavage.European journal of biochemistry, 266 2
Y. Ala, D. Morin, B. Mouillac, N. Sabatier, R. Vargas, N. Cotte, M. Déchaux, Corinne Antignac, M. Arthus, M. Lonergan, M. Turner, M. Balestre, G. Alonso, Marcel Hibert, C. Barberis, Geoffrey Hendy, D. Bichet, S. Jard (1998)
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype.Journal of the American Society of Nephrology : JASN, 9 10
N. Guex, M. Peitsch (1997)
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingELECTROPHORESIS, 18
O. Kisselev, J. Kao, J. Ponder, Y. Fann, N. Gautam, G. Marshall (1998)
Light-activated rhodopsin induces structural binding motif in G protein alpha subunit.Proceedings of the National Academy of Sciences of the United States of America, 95 8
M. Wheatley, S. Hawtin, V. Wesley, H. Howard, J. Simms, A. Miles, K. McEwan, R. Parslow (2001)
Agonist binding to peptide hormone receptors.Biochemical Society transactions, 31 Pt 1
N. Cotte, M. Balestre, A. Aumelas, E. Mahé, S. Phalipou, D. Morin, M. Hibert, M. Manning, T. Durroux, C. Barberis, B. Mouillac (2000)
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.European journal of biochemistry, 267 13
Y. Hakak, Devin Shrestha, Moira Goegel, D. Behan, D. Chalmers (2003)
Global analysis of G‐protein‐coupled receptor signaling in human tissuesFEBS Letters, 550
Sugimoto, Masayuki Saito, Shinobu Mochizuki, Yuka, Watanabe, Seiichi Hashimoto, Hiroyuki KawashimaS (1994)
Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.The Journal of biological chemistry, 269 43
S. Schulman, A. Stokes, P. Salzman (2001)
The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis.The Journal of urology, 166 6
C. Galés, A. Kowalski‐Chauvel, M. Dufour, C. Seva, L. Moroder, L. Pradayrol, N. Vaysse, D. Fourmy, S. Silvente-Poirot (2000)
Mutation of Asn-391 within the Conserved NPXXY Motif of the Cholecystokinin B Receptor Abolishes Gq Protein Activation without Affecting Its Association with the Receptor*The Journal of Biological Chemistry, 275
S. Hawtin, V. Wesley, R. Parslow, J. Simms, A. Miles, K. McEwan, M. Wheatley (2002)
A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.Molecular endocrinology, 16 3
Søren Rasmussen, A. Jensen, G. Liapakis, P. Ghanouni, J. Javitch, U. Gether (1999)
Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6.Molecular pharmacology, 56 1
Marc Thibonnier, L. Berti-Mattera, N. Dulin, D. Conarty, Rafael Mattera (1998)
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors.Progress in brain research, 119
Sybyl 6.8, Tripos Inc. 1699 South Hanley Rd., St. Louis, MO 63144, USA
E. Martin, S. Rens‐Domiano, P. Schatz, H. Hamm (1996)
Potent Peptide Analogues of a G Protein Receptor-binding Region Obtained with a Combinatorial Library (*)The Journal of Biological Chemistry, 271
S. Zhu, Shou-Zhen Wang, Jingru Hu, E. El-Fakahany (1994)
An arginine residue conserved in most G protein-coupled receptors is essential for the function of the m1 muscarinic receptor.Molecular pharmacology, 45 3
P. Cieplak, W. Cornell, C. Bayly, P. Kollman (1995)
Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteinsJournal of Computational Chemistry, 16
D. Richardson, A. Robinson (1985)
Drugs Five Years Later: DesmopressinAnnals of Internal Medicine, 103
I. Fukuda, N. Hizuka, K. Takano (2003)
Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: experience of five-year treatment.Endocrine journal, 50 4
D. Teller, T. Okada, T. Okada, C. Behnke, C. Behnke, K. Palczewski, R. Stenkamp (2001)
Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs).Biochemistry, 40 26
D. Langs, G. Smith, J. Stezowski, R. Hughes (1986)
Structure of pressinoic acid: the cyclic moiety of vasopressin.Science, 232 4755
M. Pasenkiewicz-Gierula, K. Murzyn, T. Róg, C. Czaplewski (2000)
Molecular dynamics simulation studies of lipid bilayer systems.Acta biochimica Polonica, 47 3
E. Ufer, R. Postina, V. Gorbulev, F. Fahrenholz (1995)
An extracellular residue determines the agonist specificity of V2 vasopressin receptorsFEBS Letters, 362
M. Rosenkilde, T. Kledal, T. Schwartz (2005)
High Constitutive Activity of a Virus-Encoded Seven Transmembrane Receptor in the Absence of the Conserved DRY Motif (Asp-Arg-Tyr) in Transmembrane Helix 3Molecular Pharmacology, 68
H. Luecke, B. Schobert, H. Richter, Jean-Philippe Cartailler, J. Lanyi (1999)
Structure of bacteriorhodopsin at 1.55 A resolution.Journal of molecular biology, 291 4
F. Corpet (1988)
Multiple sequence alignment with hierarchical clustering.Nucleic acids research, 16 22
E. Chruscinska, I. Derdowska, H. Kozłowski, B. Lammek, Marek Łuczkowski, S. Ołdziej, J. Świątek-Kozłowska (2003)
Unusual gain in the coordination ability of vasopressin-like peptides towards Cu2+ ions by insertion of the highly hydrophobic side chainNew Journal of Chemistry, 27
E. Albertazzi, D. Zanchetta, P. Barbier, S. Faranda, A. Frattini, P. Vezzoni, M. Procaccio, A. Bettinelli, F. Guzzi, M. Parenti, B. Chini (2000)
Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families.Journal of the American Society of Nephrology : JASN, 11 6
R. Postina, E. Ufer, R. Pfeiffer, N. Knoers, F. Fahrenholz (2000)
Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidusMolecular and Cellular Endocrinology, 164
Sujata Acharjee, J. Do‐Régo, D. Oh, R. Ahn, H. Choe, H. Vaudry, Kyungjin Kim, J. Seong, H. Kwon (2004)
Identification of Amino Acid Residues That Direct Differential Ligand Selectivity of Mammalian and Nonmammalian V1a Type Receptors for Arginine Vasopressin and VasotocinJournal of Biological Chemistry, 279
Y. Pan, P. Wilson, J. Gitschier (1994)
The effect of eight V2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin.The Journal of biological chemistry, 269 50
(2000)
Cza- plewski, C
J. Bockaert, Jean Pin (1999)
Molecular tinkering of G protein‐coupled receptors: an evolutionary successThe EMBO Journal, 18
N. Cotte, M. Balestre, Sylvie Phalipou, M. Hibert, M. Manning, C. Barberis, B. Mouillac (1998)
Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor*The Journal of Biological Chemistry, 273
Elodie Archer, B. Maigret, C. Escrieut, L. Pradayrol, D. Fourmy (2003)
Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?Trends in pharmacological sciences, 24 1
B. Mouillac, B. Chini, M. Balestre, J. Elands, S. Trumpp-Kallmeyer, J. Hoflack, M. Hibert, S. Jard, C. Barberis (1995)
The Binding Site of Neuropeptide Vasopressin V1a ReceptorThe Journal of Biological Chemistry, 270
V Hruby, M Chow, D Smith (1990)
Conformational and structural considerations in oxytocin-receptor binding and biological activity.Annual review of pharmacology and toxicology, 30
S. Kirkpatrick, C. Gelatt, Mario Vecchi (1983)
Optimization by Simulated AnnealingScience, 220
J. Morello, A. Salahpour, U. Petäjä-Repo, A. Laperrière, M. Lonergan, M. Arthus, I. Nabi, D. Bichet, M. Bouvier (2001)
Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.Biochemistry, 40 23
D. Gillessen, V. Vigneaud (1967)
The synthesis and pharmacological properties of 4-decarboxamido-8-lysine-vasopressin, 5-decarboxamido-8-lysine-vasopressin, and their 1-deamino analogues.The Journal of biological chemistry, 242 20
Jay Janz, D. Farrens (2004)
Rhodopsin Activation Exposes a Key Hydrophobic Binding Site for the Transducin α-Subunit C Terminus*Journal of Biological Chemistry, 279
M. Birnbaumer, A. Seibold, S. Gilbert, M. Ishido, C. Barberis, A. Antaramián, P. Brabet, W. Rosenthal (1992)
Molecular cloning of the receptor for human antidiuretic hormoneNature, 357
T. Kimura, O. Tanizawa, K. Mori, M. Brownstein, H. Okayama (1992)
Structure and expression of a human oxytocin receptorNature, 356
B. Koenig (2002)
Structure and Orientation of Ligands Bound to Membrane Proteins Are Reflected by Residual Dipolar Couplings in Solution NMR MeasurementsChemBioChem, 3
Francesca Fanelli, Pascaline Barbier, D. Zanchetta, P. Benedetti, Bice Chini (1999)
Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis.Molecular pharmacology, 56 1
G. Morris, D. Goodsell, R. Halliday, R. Huey, W. Hart, R. Belew, A. Olson (1998)
Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJournal of Computational Chemistry, 19
(1981)
Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart,
S. Hawtin (2005)
Charged Residues of the Conserved DRY Triplet of the Vasopressin V1a Receptor Provide Molecular Determinants for Cell Surface Delivery and InternalizationMolecular Pharmacology, 68
L. Oliveira, Tim Hulsen, D. Hulsik, A. Paiva, G. Vriend (2004)
Heavier‐than‐air flying machines are impossibleFEBS Letters, 564
M. Arthus, M. Lonergan, M. Crumley, A. Naumova, D. Morin, L. Marco, B. Kaplan, G. Robertson, S. Sasaki, K. Morgan, D. Bichet, T. Fujiwara (2000)
Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus.Journal of the American Society of Nephrology : JASN, 11 6
R. Ślusarz, J. Ciarkowski (2004)
Interaction of class A G protein-coupled receptors with G proteins.Acta biochimica Polonica, 51 1
M. Zaoral (2009)
Vasopressin analogs with high and specific antidiuretic activity.International journal of peptide and protein research, 25 6
Juan Ballesteros, Krzysztof Palczewski (2001)
G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin.Current opinion in drug discovery & development, 4 5
D. Farrens, C. Altenbach, Keumchul Yang, W. Hubbell, H. Khorana (1996)
Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of RhodopsinScience, 274
F. Solis, R. Wets (1981)
Minimization by Random Search TechniquesMath. Oper. Res., 6
M. Ślusarz, R. Ślusarz, J. Ciarkowski (2006)
Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin—modeling of an activated stateJournal of Peptide Science, 12
M. Ślusarz, A. Giełdoń, R. Ślusarz, J. Trojnar, R. Meadows, J. Ciarkowski (2005)
Study of New Oxytocin Antagonist Barusiban (Fe200 440) Affinity Toward Human Oxytocin Receptor Versus Vasopressin V1a and V2 Receptors – Molecular Dynamics Simulation in POPC BilayerQsar & Combinatorial Science, 24
M. Ślusarz, R. Ślusarz, R. Kazmierkiewicz, J. Trojnar, K. Wiśniewski, J. Ciarkowski (2003)
Molecular modeling of the neurohypophyseal receptor/atosiban complexes.Protein and peptide letters, 10 3
Claude Barberis, E. Tribollet (1996)
Vasopressin and oxytocin receptors in the central nervous system.Critical reviews in neurobiology, 10 1
R. Postina, E. Kojro, F. Fahrenholz (1996)
Separate Agonist and Peptide Antagonist Binding Sites of the Oxytocin Receptor Defined by Their Transfer into the V2 Vasopressin Receptor*The Journal of Biological Chemistry, 271
The vasopressin V2 receptor (V2R) belongs to the Class A G protein–coupled receptors (GPCRs). V2R is expressed in the renal collecting duct (CD), where it mediates the antidiuretic action of the neurohypophyseal hormone arginine vasopressin (CYFQNCPRG‐NH2, AVP). Desmopressin ((1‐deamino, 8‐D)AVP, dDAVP) is strong selective V2R agonist with negligible pressor and uterotonic activity. In this paper, the interactions responsible for binding of dDAVP to vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors has been examined. Three‐dimensional activated models of the receptors were constructed using the multiple sequence alignment and the complex of activated rhodopsin with Gtα C‐terminal peptide of transducin MII–Gtα (338–350) prototype (Ślusarz, R.; Ciarkowski, J. Acta Biochim Pol 2004 51, 129–136) as a template. The 1‐ns unconstrained molecular dynamics (MD) of receptor–dDAVP complexes immersed in the fully hydrated 1‐palmitoyl‐2‐oleoyl‐sn‐glycero‐3‐phosphatidylcholine (POPC) membrane model was conducted in an Amber 7.0 force field. Highly conserved transmembrane residues have been proposed as being responsible for V2R activation and G protein coupling. Molecular mechanism of the dDAVP binding has been suggested. The internal water molecules involved in an intricate network of the hydrogen bonds inside the receptor cavity have been identified and their role in the stabilization of the agonist‐bound state proposed. © 2005 Wiley Periodicals, Inc. Biopolymers 81: 321–338, 2006 This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com
Biopolymers – Wiley
Published: Apr 5, 2006
Keywords: desmopressin; dDAVP; GPCR; internal water; MD; receptor activation; V2R
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.